Chinese Medicine WT for Spinocerebellar Ataxia Type 3
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05038306 |
Recruitment Status :
Completed
First Posted : September 9, 2021
Last Update Posted : January 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Spinocerebellar ataxia type 3 (SCA3) is one of autosomal dominant hereditary ataxias. Standing imbalance, unsteady gait, dysmetria, fatigue, and depression would occur gradually. There are no effective treatment or palliative methods for patients in the present days. However, low-dose growth hormone, or its downstream product, insulin-like growth factor I (IGF-1), may deter the progress of SCA3 in transgenic mice. The main bioactive constituent among the Chinese medicine WT possesses neuroprotective function against glutamate-induced toxicity, which is one major pathology of SCA3. It promotes neurogenesis, and increases the protein expression of IGF-1 in ischemic brains of rats. Thus, we designed a randomized, double-blind trial for patients with SCA3, if WT is a possible neuroprotective medicine.
All the subjects will be recruited from Changhua Christian Hospital. Diagnosis is confirmed by gene test and magnetic resonance image by a neurologist. They will be assigned in random and double blind, prescribed with 3 grams concentrated powder of WT or placebo, twice a day, for 12 weeks. After the washout period of 4 weeks, there will be a crossover of placebo or WT for another 12 weeks. After that, another 4-week rest will be followed by the end of trial. Check items in five check points include: 1. Blood examination (serum IGF-1, Neurofilament light chain, mitochondria copy number, 8_OHdG, delta-Ct), 2.Neurological exam (Scale for the Assessment and Rating of Ataxia), 3. Questionnaires (Modified Fatigue Impact Scale, Epworth Sleepiness Scale), 4. Handgrip strength test (which is correlated to IGF-1 value in elderly), and 5. serum metabolites, . All the data will be disclosed after the end of trial. Paired-T test or Wilcoxon Ranked Sign Test will be operated in SPSS.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ataxia, Spinocerebellar Insulin-Like Growth Factor I Medicine, Chinese Traditional | Drug: Chinese medicine WT | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 33 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Chinese Medicine WT for Elevating IGF-1 of Patients With Spinocerebellar Ataxia Type 3 - Pilot Study |
Actual Study Start Date : | May 31, 2021 |
Actual Primary Completion Date : | September 26, 2022 |
Actual Study Completion Date : | September 26, 2022 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Chinese Medicine |
Drug: Chinese medicine WT
The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia. |
Placebo Comparator: Placebo |
Drug: Chinese medicine WT
The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia. |
- Change from baseline in Insulin-like Growth Factor 1 at week 12, or from week 16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks, 32 weeks ]Insulin-like growth factor I is appropriate to observe the change for a period instead of the absolute value.
- Change from baseline in Neurofilament light Chain at week 12, or from week 16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks, 32 weeks ]Neurofilament light Chain is appropriate to observe the change for a period instead of the absolute value
- Change from baseline in scale for the assessment and rating of ataxia(SARA) at week 12, or from week 16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]scores of SARA are from 0 to 40, with higher scores means worse outcome
- Change from baseline in Modified Fatigue Impact Scale (MFIS) at week 12, or from week 16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]scores of MFIS are from 0 to 84, with higher scores means worse outcome
- Change from baseline in Epworth Sleepiness Scale (ESS) at week 12, or from week16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]scores of ESS are from 0 to 24, with higher scores means worse outcome
- Change from baseline in Hand-grip strength test (HST) at week 12, or from week16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]HST is appropriate to observe the change for a period instead of the absolute value
- Change from baseline in mitochondria DNA (mtDNA) at week 12, or from week16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]mitochondrial DNA HST is appropriate to observe the change for a period instead of the absolute value
- Change from baseline in 8_OHdG at week 12, or from week16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]8_OHdG is appropriate to observe the change for a period instead of the absolute value
- Change from baseline in △Ct at week 12, or from week16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]△Ct is appropriate to observe the change for a period instead of the absolute value
- Change from baseline in serum metabolites at week 12, or from week 16 to week 28 [ Time Frame: baseline and 12 weeks, or 16 weeks and 28 weeks ]serum metabolites is appropriate to observe the change for a period instead of the absolute value. Till now, there was no sufficient data about the metabolites of Chinese WT, so we would like to measure the difference of metabolites before and after taking the Chinese medicine WT.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosed as Spinocerebellar Ataxia type 3
Exclusion Criteria:
- 1. using other Chinese medicine or herbal medicine 2. allergic to Chinese medicine or herbal medicine 3. pregnancy or breast feeding 4. with other major diseases, such as cancer, stroke, heart failure, or renal failure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05038306
Taiwan | |
Changhua Christian Hospital | |
Changhua, Taiwan, 500 |
Responsible Party: | Chiu Chung Min, Adjunct Physician, Changhua Christian Hospital |
ClinicalTrials.gov Identifier: | NCT05038306 |
Other Study ID Numbers: |
200703 |
First Posted: | September 9, 2021 Key Record Dates |
Last Update Posted: | January 31, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ataxia Cerebellar Ataxia Spinocerebellar Ataxias Spinocerebellar Degenerations Machado-Joseph Disease Dyskinesias Neurologic Manifestations Nervous System Diseases |
Cerebellar Diseases Brain Diseases Central Nervous System Diseases Spinal Cord Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn |